Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

Visual Abstract

[1]  W. Leisenring,et al.  Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms , 2022, Leukemia.

[2]  A. Subramanian,et al.  Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia , 2022, Leukemia & lymphoma.

[3]  S. Fleming,et al.  Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021 , 2021, Internal medicine journal.

[4]  W. Hogan,et al.  Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC , 2018, Blood.

[5]  E. Estey,et al.  Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms , 2018, Haematologica.

[6]  C. Flowers,et al.  Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Ljungman,et al.  European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.

[8]  E. Estey,et al.  Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms , 2018, Leukemia.

[9]  J. Perfect,et al.  Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Pagano,et al.  Risks for infection in patients with myelodysplasia and acute leukemia , 2012, Current opinion in infectious diseases.

[11]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. DeAngelo,et al.  Invasive fungal disease in patients treated for newly diagnosed acute leukemia , 2010, American journal of hematology.

[13]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[14]  J. Perfect,et al.  Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[15]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  T. Robak,et al.  Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group , 2007, European journal of haematology.

[17]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[18]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.

[19]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .